Aligos Therapeutics (ALGS) announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company’s global clinical development efforts and serve as a member of Aligos’ Senior Leadership Team. Most recently, Dr. Achneck served as the Senior Vice President and Head of Clinical Development at Pliant Therapeutics (PLRX) where he oversaw all clinical programs, including those in hepatic diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics management to meet virtually with Piper Sandler
- Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
- Aligos Therapeutics announces results from Phase 2a HERALD study
- Closing Bell Movers: Steelcase down 10% on soft top-line results, guidance
- Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024